[1] |
史雪辉,张丛,魏文斌. 关注糖尿病黄斑水肿的光学相干断层扫描分型及相关影像特征[J]. 中华眼科医学杂志(电子版),2021,11(1):1-7.
|
[2] |
Mehta RK, Koirala P, Mallick RL, et al. Dyslipidemia in patients with type 2 diabetes mellitus in a tertiary care centre: a descriptive cross-sectional study[J]. JNMA J Nepal Med Assoc, 2021, 59(236): 305-309.
|
[3] |
Kinuthia UM, Wolf A, Langmann T. Microglia and inflammatory responses in diabetic retinopathy[J]. Front Immunol, 2020, 11: 564077.
|
[4] |
Busik JV. Lipid metabolism dysregulation in diabetic retinopathy[J]. J Lipid Res, 2021, 62: 100017.
|
[5] |
Sasso FC, Pafundi PC, Gelso A, et al. High HDL cholesterol: A risk factor for diabetic retinopathy? Findings from NO BLIND study[J]. Diabetes Res Clin Pract, 2019, 150: 236-244.
|
[6] |
中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中国循环杂志,2023,38(3):237-271.
|
[7] |
Xuan J, Wang L, Fan L, et al. Systematic review and meta-analysis of the related factors for diabetic retinopathy[J]. Ann Palliat Med, 2022, 11(7): 2368-2381.
|
[8] |
Wei Q, Qiu W, Liu Q, et al. Relationship between risk factors and macular thickness in patients with early diabetic retinopathy[J]. Int J Gen Med, 2022, 15: 6021-6029.
|
[9] |
王凯悦,张新媛,聂瑶,等.脂类代谢异常与糖尿病视网膜微血管病变及神经元退行性改变的相关性研究[J]. 中华眼科医学杂志(电子版),2020,10(4):212-218.
|
[10] |
Gungel H, Aral H, Erdenen F, et al. Central macular thickness in diabetic macular edema[J]. Acta Endocrinol (Buchar), 2020, 16(4): 417-425.
|
[11] |
Julve J, Rossell J, Correig E, et al. Predictive value of the advanced lipoprotein profile and glycated proteins on diabetic retinopathy[J]. Nutrients, 2022, 14(19): 3932.
|
[12] |
Zhou Y, Wang C, Shi K, et al. Relationship between dyslipidemia and diabetic retinopathy: A systematic review and meta-analysis[J]. Medicine (Baltimore), 2018, 97(36): e12283.
|
[13] |
Cetin EN, Bulgu Y, Ozdemir S, et al. Association of serum lipid levels with diabetic retinopathy[J]. Int J Ophthalmol, 2013, 6(3): 346-349.
|
[14] |
Hukportie DN, Li FR, Zhou R, et al. Lipid variability and risk of microvascular complications in Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: A post hoc analysis[J]. J Diabetes, 2022, 14(6): 365-376.
|
[15] |
Emanuelsson F, Nordestgaard BG, Tybjerg-Hansen A, et al. Impact of LDL cholesterol on microvascular versus macrovascular disease: a mendelian randomization study[J]. J Am Coll Cardiol, 2019, 74(11): 1465-1476.
|
[16] |
Mehta A, Shapiro MD. Apolipoproteins in vascular biology and atherosclerotic disease[J]. Nat Rev Cardiol, 2022, 19(3): 168-179.
|
[17] |
Bhattacharjee PS, Huq TS, Potter V, et al. High-glucose-induced endothelial cell injury is inhibited by a Peptide derived from human apolipoprotein E[J]. PLoS One, 2012, 7(12): e52152.
|
[18] |
Saucedo L, Pfister IB, Schild C, et al. Aqueous humor apolipoprotein concentration and severity of diabetic retinopathy in type 2 diabetes[J]. Mediators Inflamm, 2022, PMID: 2406322.
|
[19] |
Van-Der-Vorst EPC. High-density lipoproteins and apolipoprotein A1[J]. Subcell Biochem, 2020, 94: 399-420.
|
[20] |
Gao L, Zhang Y, Wang X, et al. Association of apolipoproteins A1 and B with type 2 diabetes and fasting blood glucose: a cross-sectional study[J]. BMC Endocr Disord, 2021, 21(1): 59.
|
[21] |
Zhang X, Nie Y, Gong Z, et al. Plasma apolipoproteins predicting the occurrence and severity of diabetic retinopathy in patients with type 2 diabetes mellitus[J]. Front Endocrinol (Lausanne), 2022, 13: 915575.
|
[22] |
Shi R, Lu Y, Liu D, et al. Association of serum apolipoprotein B with retinal neurovascular structural alterations in patients with type 2 diabetes: an optical coherence tomography angiography study[J]. Acta Diabetol, 2021, 58(12): 1673-1681.
|
[23] |
Zou C, Han C, Zhao M, et al. Change of ranibizumab-induced human vitreous protein profile in patients with proliferative diabetic retinopathy based on proteomics analysis[J]. Clin Proteomics, 2018, 15: 12.
|
[24] |
Kurooka N, Eguchi J, Wada J. Role of glycosylpho-sphatidylinositol-anchored high-density lipoprotein binding protein 1 in hypertriglyceridemia and diabetes[J].J Diabetes Investig, 2023, 14(10): 1148-1156.
|
[25] |
Overgaard M, Ravnsborg T, Lohse Z, et al. Apolipoprotein D and transthyretin are reduced in female adolescent offspring of women with type 1 diabetes: The EPICOM study[J]. Diabet Med, 2022, 39(7): e14776.
|
[26] |
Masuda T, Shimazawa M, Hashimoto Y, et al. Apolipoprotein E2 and E3, but not E4, promote retinal pathologic neovascularization[J]. Invest Ophthalmol Vis Sci, 2017, 58(2): 1208-1217.
|
[27] |
Liu Z, Shao M, Ren J, et al. Association between increased lipid profiles and risk of diabetic retinopathy in a population-based case-control study[J]. J Inflamm Res, 2022, 15: 3433-3446.
|
[28] |
Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on Lipoprotein(a): A call to action [J]. Atherosclerosis, 2019, 291: 62-70.
|
[29] |
Moosaie F, Davatgari RM, Firouzabadi FD, et al. Lipoprotein(a) and apolipoproteins as predictors for diabetic retinopathy and its severity in adults with type 2 diabetes: a case-cohort study[J]. Can J Diabetes, 2020, 44(5): 414-421.
|
[30] |
Tu WJ, Liu H, Liu Q, et al. Association between serum lipoprotein(a)and diabetic retinopathy in han Chinese patients with type 2 diabetes[J]. J Clin Endocrinol Metab, 2017, 102(7): 2525-2532.
|
[31] |
Nishikura T, Koba S, Yokota Y, et al. Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease[J]. J Atheroscler Thromb, 2014, 21(8): 755-67.
|
[32] |
Nakayama A, Morita H, Sato T, et al. Small dense low-density lipoprotein cholesterol is a potential marker for predicting laser treatment for retinopathy in diabetic patients[J]. J Atheroscler Thromb, 2022, 29(5): 678-691.
|
[33] |
Eid S, Sas KM, Abcouwer SF, et al. New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism[J]. Diabetologia, 2019, 62(9): 1539-1549.
|
[34] |
Gong Y, Fu Z, Liegl R, et al. ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases[J]. Am J Clin Nutr, 2017, 106(1): 16-26.
|
[35] |
Sala-Vila A, Díaz-López A, Valls-Pedret C, et al. Dietary marine ω-3 fatty acids and incident sight-threatening retinopathy in middle-aged and older individuals with type 2 diabetes: prospective investigation from the PREDIMED trial[J]. JAMA Ophthalmol, 2016, 134(10): 1142-1149.
|
[36] |
Zhao S, Jin D, Wang S, et al. Serum ω-6/ω-3 polyunsaturated fatty acids ratio and diabetic retinopathy: A propensity score matching based case-control study in China[J]. EClinical Medicine, 2021, 39: 101089.
|
[37] |
Raman R, Ganesan S, Pal SS, et al. Incidence and progression of diabetic retinopathy in urban india: sankara nethralaya-diabetic retinopathy epidemiology and molecular genetics study (SN-DREAMS Ⅱ), Report 1[J]. Ophthalmic Epidemiol, 2017, 24(5): 294-302.
|
[38] |
王夏叶,刘莹,徐丽霞. 血脂指标比值对2型糖尿病视网膜病变的预测价值[J]. 中国卫生检验杂志,2021,31(7):859-861,865.
|
[39] |
胡邵宁,朱书渊,魏燕斌. 血清脂蛋白a水平及三酰甘油与高密度脂蛋白胆固醇比值与2型糖尿病视网膜病变的相关性研究[J]. 中国卫生检验杂志,2022,32(2):205-208.
|
[40] |
Zhang Q, Hu J, Hu Y, et al. Relationship between serum apolipoproteins levels and retinopathy risk in subjects with type 2 diabetes mellitus[J]. Acta Diabetol, 2018, 55(7): 681-689.
|
[41] |
Kang EY, Chen TH, Garg SJ, et al. Association of statin therapy with prevention of vision-threatening diabetic retinopathy[J]. JAMA Ophthalmol, 2019, 137(4): 363-371.
|
[42] |
Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study[J]. Lancet Diabetes Endocrinol, 2014, 2(11): 894-900.
|
[43] |
Chatziralli IP. The role of dyslipidemia control in the progression of diabetic retinopathy in patients with type 2 diabetes mellitus[J]. Diabetes Ther, 2017, 8(2): 209-212.
|
[44] |
Tuuminen R, Sahanne S, Loukovaara S. Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment[J]. Acta Ophthalmol, 2014, 92(7): 675-681.
|
[45] |
Pranata R, Vania R, Victor AA. Statin reduces the incidence of diabetic retinopathy and its need for intervention: A systematic review and meta-analysis[J]. Eur J Ophthalmol, 2021, 31(3): 1216-1224.
|
[46] |
Pearsall EA, Cheng R, Matsuzaki S, et al. Neuroprotective effects of PPARα in retinopathy of type 1 diabetes[J]. PLoS One, 2019, 14(2): e0208399.
|
[47] |
Ruan Y, Jiang S, Musayeva A, et al. Oxidative stress and vascular dysfunction in the retina: therapeutic strategies[J]. Antioxidants (Basel), 2020, 9(8): 761.
|
[48] |
Tomita Y, Lee D, Tsubota K, et al. PPARα agonist oral therapy in diabetic retinopathy[J]. Biomedicines, 2020, 8(10): 433.
|
[49] |
Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the action to control cardiovascular risk in diabetes (ACCORD) Follow-On Study[J]. Diabetes Care, 2016, 39(7): 1089-100.
|
[50] |
Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial[J]. Lancet, 2005, 366(9500): 1849-1861.
|
[51] |
Zhou X, Ai S, Chen Z, et al. Probucol promotes high glucose-induced proliferation and inhibits apoptosis by reducing reactive oxygen species generation in Müller cells[J]. Int Ophthalmol, 2019, 39(12): 2833-2842.
|
[52] |
Liu HW, Luo Y, Zhou YF, et al. Probucol prevents diabetes-induced retinal neuronal degeneration through upregulating Nrf2[J]. Biomed Res Int, 2022, PMID: 32149102.
|
[53] |
Liu H, Cai M. Effect of probucol on hemodynamics, rheology and blood lipid of diabetic retinopathy[J]. Exp Ther Med, 2018, 15(4): 3809-3814.
|
[54] |
Mazzoli V, Zhong LH, Dang VT, et al. Characterization of retinal microvascular complications and the effects of endoplasmic reticulum stress in mouse models of diabetic atherosclerosis[J]. Invest Ophthalmol Vis Sci, 2020, 61(10): 49.
|